Boronic Acid Liphagane Compounds for PI3K Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors face challenges with low potency, poor isoform selectivity, limited stability, and unacceptable pharmacological and pharmacokinetic properties, making them ineffective as anticancer therapies.
Innovation Solution
Development of boronic acid bearing liphagane compounds that act as specific inhibitors of PI3K-α/β isoforms, utilizing a synthetic route involving boronic acid functionalization and specific structural modifications to enhance their anticancer activity and isoform selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If natural product based small molecules (Wortmannin, LY294002) are used as PI3K inhibitors, then nano-gram range IC50 values are achieved, but poor isoform selectivity and limited stability prevent market approval
Solution Approach 1:
The patent introduces a boronic acid moiety at a specific position of the liphagane scaffold, creating localized chemical functionality that enhances binding selectivity to PI3K-α/β isoforms while maintaining overall molecular stability. This local modification allows differential interaction with target isoforms without compromising general molecular properties
Solution Approach 2:
The patent systematically varies substituents at positions R1, R2, R3, R4, R5, R6, and R7 of the liphagane scaffold, optimizing parameters such as hydrophobicity, steric bulk, and electronic properties to enhance both potency (IC50) and isoform selectivity. The boronic acid group specifically targets parameter optimization for covalent binding to cysteine residues in PI3K-α/β active sites
2Adaptability or versatility
If broad spectrum PI3K inhibition is achieved, then therapeutic potential against multiple cancer types is enhanced, but poor tolerability due to essential physiological processes worsens
Solution Approach 1:
The boronic acid functional group provides localized specificity by forming reversible covalent bonds with cysteine residues in the ATP-binding pocket of PI3K-α and PI3K-β isoforms. This local chemical interaction enables selective inhibition of oncogenic isoforms while sparing other PI3K family members involved in normal physiological processes
Solution Approach 2:
Instead of designing inhibitors that broadly block all PI3K isoforms, the patent inverts the approach by creating compounds with inverted selectivity - specifically targeting only the oncogenic PI3K-α and PI3K-β isoforms through the boronic acid moiety, thereby achieving therapeutic efficacy while minimizing off-target effects on physiological processes
3Quantity of substance
If previous PI3K inhibitors were developed, then initial anticancer activity was observed, but low potency and poor pharmacokinetic properties made them ineffective
Solution Approach 1:
The patent combines the liphagane natural product scaffold (which provides membrane permeability and cellular uptake properties) with a boronic acid functional group (which provides covalent binding capability and isoform selectivity). This composite structure integrates the advantages of both components to achieve potent anticancer activity with improved pharmacokinetic properties
Solution Approach 2:
The boronic acid group is pre-positioned on the liphagane scaffold to enable preliminary covalent interaction with the cysteine residue in the PI3K active site upon cellular entry. This preliminary binding action ensures rapid and potent inhibition of the target enzyme, overcoming the low potency issues of previous reversible inhibitors
Data Source
AI summary
Compounds with unique liphagane meroterpenoid scaffold having boronic acid functionality in the skeleton are described (formula 1) together with pharmacological potential of these compounds as anticancer agents. A method of preparation and inhibiting the activity of phosphoinositide-3-kinase (PI3K-alpha and beta) has been presented. In particular, the invention describes a method of inhibiting PI3K isoforms, wherein the compounds are novel structures based on liphagane scaffold with unique boronic acid functionality. The methods and uses thereof are described herein this invention.